VYNE

Company Announcement: VYNE Therapeutics Inc. will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, with a fireside chat scheduled for 11:00 am ET.

About VYNE: The company focuses on developing innovative therapies for chronic inflammatory and immune-mediated conditions, utilizing its proprietary BET inhibitors to enhance treatment effectiveness.

Paymentus Holdings Performance: Paymentus Holdings, Inc. shares rose 8.4% in pre-market trading after reporting better-than-expected fourth-quarter earnings of 13 cents per share and sales of $257.88 million, surpassing analyst estimates.

Market Movements: Several stocks experienced significant pre-market trading changes, with Aspira Women’s Health rising 103.4%, while NET Power saw a decline of 35.4% following disappointing earnings results.

Analyst Ratings Overview: VYNE Therapeutics has received mixed ratings from analysts over the last quarter, with a consistent average price target of $5.75, reflecting a stable outlook despite varying sentiments among five analysts.

Company Financial Insights: VYNE Therapeutics shows positive revenue growth of approximately 6.14%, but struggles with profitability indicated by a net margin of -10047.11%. The company maintains a prudent financial strategy with a low debt-to-equity ratio.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Insider Purchase: Patrick G. Lepore of VYNE Therapeutics purchased 15,000 shares at $2.92 each, totaling $43,800, marking his first buy in the past year.

Stock Performance: VYNE's stock is currently trading lower than Lepore's purchase price at $2.77, despite a 10.5% increase on Friday.

VYN201 Gel Trial: VYNE Therapeutics has completed enrollment for a Phase 2b trial of its once-daily VYN201 gel, now named repibresib, aimed at treating nonsegmental vitiligo, with top-line data expected in mid-2025.

Vitiligo Overview: Vitiligo is a common autoimmune skin disorder affecting 0.5-2.0% of the global population, and currently, there is only one FDA-approved treatment available for it.

Analyst Coverage: BTIG analyst Julian Harrison has initiated coverage of VYNE Therapeutics with a Buy rating and a price target of $8.00, while the stock currently trades at $3.35.

Market Consensus: VYNE Therapeutics holds a Strong Buy consensus among analysts, with an average price target of $6.19, indicating significant upside potential from its current market cap of $49.42M.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

VYN202 Trial Results: VYNE Therapeutics announced promising results from the Phase 1a trial of VYN202, showing a favorable safety profile with no serious adverse events and robust pharmacodynamic activity against inflammatory biomarkers in immune-mediated disorders.

Potential Impact: The data supports VYN202's potential as a novel once-daily oral treatment option for chronic inflammatory conditions, addressing limitations of earlier BET inhibitors while demonstrating effective target engagement and tolerability.

Menlo Security's Financial Growth: Menlo Security has surpassed $100 million in annual recurring revenue, marking a 30% increase from the previous year, and aims to be cash flow positive by 2025 without needing additional funding.

Expansion Plans and Market Strategy: The company is focusing on global expansion and partnerships with major firms like Google, while also considering acquisitions to enhance its security offerings.

Analyst Ratings: Rami Katkhuda from LifeSci Capital maintains a Buy rating on VYNE Therapeutics with a $6.00 price target, citing positive early results from the Phase Ia trial of VYN202 and its potential for clinical efficacy in treating psoriasis and rheumatoid arthritis.

Company Overview: VYNE Therapeutics focuses on developing treatments for dermatologic conditions, including pruritus associated with atopic dermatitis and psoriasis, and has plans for further studies with topline results expected in 2025.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Earnings Report Overview: VYNE Therapeutics reported a second quarter 2024 earnings per share of -22 cents, missing the analyst estimate of -19 cents, while revenue reached $198,000, exceeding expectations of $110,000 by 80%.

Automated Earnings Coverage: InvestorPlace Earnings utilizes TradeSmith data to provide automated coverage of quarterly earnings reports, delivering key financial metrics quickly and efficiently without human intervention.

Rigel Pharmaceuticals Earnings Report: Rigel Pharmaceuticals reported a quarterly loss of $0.06 per share, significantly better than the expected loss of $0.37, and achieved revenues of $36.84 million, exceeding estimates by 13.79%. The company has surpassed consensus EPS estimates three times in the last four quarters.

Stock Performance Outlook: Despite underperforming the market with a 39.3% decline this year, Rigel's future stock performance will depend on management's commentary and earnings estimate revisions, currently holding a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

Analyst Ratings Overview:

• Recent insights from 4 analysts on VYNE Therapeutics show varying sentiments from bullish to bearish.
• Average price target remains at $5.75 with no changes, reflecting stability in analyst predictions.
• Analysts frequently update ratings based on market conditions and company performance.

VYNE Therapeutics Company Profile:

• VYNE Therapeutics focuses on developing therapies for immuno-inflammatory conditions.
• Their product candidate FMX114 targets mild-to-moderate AD, while also exploring BET inhibitor compounds.
• Products include AMZEEQ, ZILXI, and FCD105.

Financial Performance Analysis:

• Market capitalization indicates a strong market presence for VYNE Therapeutics.
• Negative revenue trend with a decline of approximately -1.01% as of March 31, 2024.
• Net margin below industry averages, but ROE and ROA perform exceptionally well.

Understanding Analyst Ratings:

• Analysts predict future company earnings and risk levels to provide stock ratings.
• They attend meetings, research financial statements, and communicate with insiders for insights.
• Analysts offer guidance on metrics like growth estimates, earnings, and revenue alongside ratings.

Importance of Analyst Ratings:

• Analyst ratings are valuable tools for investors, but they are opinions subject to human error.
• Benzinga tracks analyst firms and their success scores to help investors make informed decisions.